Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Lowered by Wall Street Zen

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research firms also recently commented on VYGR. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a report on Thursday, August 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $1.86 on Friday. The firm has a market cap of $116.06 million, a price-to-earnings ratio of -1.08 and a beta of 1.20. The stock has a fifty day simple moving average of $2.55 and a two-hundred day simple moving average of $3.41. Voyager Therapeutics has a 12 month low of $1.68 and a 12 month high of $5.48.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.01. The firm had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $6.35 million. Voyager Therapeutics had a negative return on equity of 59.83% and a negative net margin of 416.32%. On average, equities research analysts forecast that Voyager Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Voyager Therapeutics in the 2nd quarter worth $18,102,000. Renaissance Technologies LLC grew its holdings in shares of Voyager Therapeutics by 95.0% in the first quarter. Renaissance Technologies LLC now owns 578,024 shares of the company’s stock worth $2,231,000 after acquiring an additional 281,574 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Voyager Therapeutics in the second quarter worth $513,000. Seven Fleet Capital Management LP purchased a new stake in Voyager Therapeutics during the first quarter valued at $445,000. Finally, Altshuler Shaham Ltd increased its position in Voyager Therapeutics by 34.4% during the first quarter. Altshuler Shaham Ltd now owns 273,925 shares of the company’s stock valued at $1,057,000 after acquiring an additional 70,185 shares during the last quarter. Institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.